Bind stock soars on 2015 update; GW Pharma as Sativex misses in PhIII; Kyowa, Syndax ink $100M license deal;

@FierceBiotech: Biogen Idec's remyelination drug raises hopes--and some fears--in Phase II. Story | Follow @FierceBiotech

@JohnCFierce: Anybody who says that statistical significance is not expected in a study is playing defense for a stock. | Follow @JohnCFierce

@DamianFierce: No FDA panel scheduled for Pizer's palbociclib, which $PFE hopes to get approved as Ibrance before April deadline. More | Follow @DamianFierce

> Bind Therapeutics ($BIND) saw its share price soar 80% this morning as the biotech laid out its 2015 strategy and updated investors on a positive mid-stage study of BIND-014 for castration-resistant prostate cancer. Release

> Shares of GW Pharmaceuticals slid this morning after the UK biotech reported that Sativex failed the first of three Phase III pain studies. Story

> Kyowa Hakko Kirin and Syndax Pharmaceuticals inked a $100 million license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Alere snags first FDA CLIA waiver for molecular influenza test. Article | Follow @FierceMedDev

@EmilyWFierce: Hedge fund exec aims new legal weapon at Big Pharma's 'evergreened' patents. Story | Follow @EmilyWFierce

> 23andMe's $60M deal with Genentech shows an alternative path forward for diagnostics companies. News

> FDA lifts import restriction on Hospira as it aims to reinvigorate its infusion pumps. Article

Pharma News

@FiercePharma: ICYMI yesterday: New study clears Merck's blockbuster Gardasil of MS risk. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Valneva picks up J&J's cholera vaccine--and some forthcoming competition. More | Follow @CarlyHFierce

> Big Pharma threatens to sue U.K. fund as officials nix Novartis, Sanofi and Eisai meds. More

> Hedge fund exec aims new legal weapon at Big Pharma's 'evergreened' patents. Article

Vaccines News

> Pfizer's growth spurt continues with pickup of Switzerland's Redvax. Report

> Swiss trial of Merck/NewLink Ebola vaccine resumes at lower dose. Article

> Valneva picks up J&J's cholera vaccine--and some forthcoming competition. Story

> No link between Merck's Gardasil and MS risk, study shows. Item

> Johnson & Johnson is third to bring Ebola vaccine to trials, but is it too late? More

Pharma Manufacturing News

> Impax Labs overcomes manufacturing issues to get Parkinson's drug approved. More

> Arena, Eisai have to recall nearly 122,000 bottles of Belviq over labeling glitch. Article

> France and Italy ban products from Indian companies. More

> Drugmakers ask Supreme Court to squelch California drug takeback law. Story

> China regulator promises action to fix 'grim' drug safety situation. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.